Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Non-viral, Tumor-free Induction of Transient Cell Reprogramming in Mouse Skeletal Muscle to Enhance Tissue Regeneration.

de Lázaro I, Yilmazer A, Nam Y, Qubisi S, Razak FMA, Degens H, Cossu G, Kostarelos K.

Mol Ther. 2019 Jan 2;27(1):59-75. doi: 10.1016/j.ymthe.2018.10.014. Epub 2018 Oct 24.

PMID:
30470628
2.

Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms.

Lazaro I, Lopez-Sanz L, Bernal S, Oguiza A, Recio C, Melgar A, Jimenez-Castilla L, Egido J, Madrigal-Matute J, Gomez-Guerrero C.

Front Pharmacol. 2018 Jul 31;9:819. doi: 10.3389/fphar.2018.00819. eCollection 2018.

3.

SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition.

Lopez-Sanz L, Bernal S, Recio C, Lazaro I, Oguiza A, Melgar A, Jimenez-Castilla L, Egido J, Gomez-Guerrero C.

Lab Invest. 2018 Oct;98(10):1276-1290. doi: 10.1038/s41374-018-0043-6. Epub 2018 Mar 14.

PMID:
29540859
4.

Transient transcription factor (OSKM) expression is key towards clinical translation of in vivo cell reprogramming.

de Lázaro I, Cossu G, Kostarelos K.

EMBO Mol Med. 2017 Jun;9(6):733-736. doi: 10.15252/emmm.201707650.

5.

Electrochemical oxidation of cyanide on 3D Ti-RuO2 anode using a filter-press electrolyzer.

Pérez T, López RL, Nava JL, Lázaro I, Velasco G, Cruz R, Rodríguez I.

Chemosphere. 2017 Jun;177:1-6. doi: 10.1016/j.chemosphere.2017.02.136. Epub 2017 Feb 28.

PMID:
28279900
6.

Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis.

Lazaro I, Oguiza A, Recio C, Lopez-Sanz L, Bernal S, Egido J, Gomez-Guerrero C.

Clin Investig Arterioscler. 2017 Mar - Apr;29(2):51-59. doi: 10.1016/j.arteri.2016.10.003. Epub 2017 Feb 7. English, Spanish.

PMID:
28188022
7.

Graphene materials as 2D non-viral gene transfer vector platforms.

Vincent M, de Lázaro I, Kostarelos K.

Gene Ther. 2017 Mar;24(3):123-132. doi: 10.1038/gt.2016.79. Epub 2016 Nov 22. Review.

PMID:
27874854
8.

Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Recio C, Lazaro I, Oguiza A, Lopez-Sanz L, Bernal S, Blanco J, Egido J, Gomez-Guerrero C.

J Am Soc Nephrol. 2017 Feb;28(2):575-585. doi: 10.1681/ASN.2016020237. Epub 2016 Sep 8.

9.

Synthesis and characterisation of a mesocyclic tripodal triamine ligand.

Ure AD, Lázaro IA, Cotter M, McDonald AR.

Org Biomol Chem. 2016 Jan 14;14(2):483-494. doi: 10.1039/c5ob01556a.

PMID:
26488232
10.

Engineering Cell Fate for Tissue Regeneration by In Vivo Transdifferentiation.

de Lázaro I, Kostarelos K.

Stem Cell Rev. 2016 Feb;12(1):129-39. doi: 10.1007/s12015-015-9624-6. Review.

PMID:
26403511
11.

Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?

Yilmazer A, de Lázaro I, Taheri H.

Cancer Lett. 2015 Dec 1;369(1):1-8. doi: 10.1016/j.canlet.2015.06.027. Epub 2015 Aug 11. Review.

PMID:
26276716
12.

Targeting HSP90 Ameliorates Nephropathy and Atherosclerosis Through Suppression of NF-κB and STAT Signaling Pathways in Diabetic Mice.

Lazaro I, Oguiza A, Recio C, Mallavia B, Madrigal-Matute J, Blanco J, Egido J, Martin-Ventura JL, Gomez-Guerrero C.

Diabetes. 2015 Oct;64(10):3600-13. doi: 10.2337/db14-1926. Epub 2015 Jun 26.

13.

Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.

Oguiza A, Recio C, Lazaro I, Mallavia B, Blanco J, Egido J, Gomez-Guerrero C.

Diabetologia. 2015 Jul;58(7):1656-67. doi: 10.1007/s00125-015-3596-6. Epub 2015 Apr 28.

PMID:
25982245
14.

Novel blaROB-1-bearing plasmid conferring resistance to β-lactams in Haemophilus parasuis isolates from healthy weaning pigs.

Moleres J, Santos-López A, Lázaro I, Labairu J, Prat C, Ardanuy C, González-Zorn B, Aragon V, Garmendia J.

Appl Environ Microbiol. 2015 May 1;81(9):3255-67. doi: 10.1128/AEM.03865-14. Epub 2015 Mar 6.

15.

Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice.

Recio C, Oguiza A, Mallavia B, Lazaro I, Ortiz-Muñoz G, Lopez-Franco O, Egido J, Gomez-Guerrero C.

Basic Res Cardiol. 2015 Mar;110(2):8. doi: 10.1007/s00395-014-0458-1. Epub 2015 Jan 21.

PMID:
25604439
16.

Peptide nanofiber complexes with siRNA for deep brain gene silencing by stereotactic neurosurgery.

Mazza M, Hadjidemetriou M, de Lázaro I, Bussy C, Kostarelos K.

ACS Nano. 2015 Feb 24;9(2):1137-49. doi: 10.1021/nn5044838. Epub 2015 Jan 21.

PMID:
25574683
17.

Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.

Recio C, Oguiza A, Lazaro I, Mallavia B, Egido J, Gomez-Guerrero C.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1953-60. doi: 10.1161/ATVBAHA.114.304144. Epub 2014 Jul 10.

PMID:
25012131
18.

Generation of induced pluripotent stem cells from virus-free in vivo reprogramming of BALB/c mouse liver cells.

de Lázaro I, Bussy C, Yilmazer A, Jackson MS, Humphreys NE, Kostarelos K.

Biomaterials. 2014 Sep;35(29):8312-20. doi: 10.1016/j.biomaterials.2014.05.086. Epub 2014 Jul 4.

PMID:
25002261
19.

Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics?

de Lázaro I, Yilmazer A, Kostarelos K.

J Control Release. 2014 Jul 10;185:37-44. doi: 10.1016/j.jconrel.2014.04.011. Epub 2014 Apr 16. Review.

PMID:
24746625
20.

In vivo reprogramming of adult somatic cells to pluripotency by overexpression of Yamanaka factors.

Yilmazer A, de Lázaro I, Bussy C, Kostarelos K.

J Vis Exp. 2013 Dec 17;(82):e50837. doi: 10.3791/50837.

21.

Intravenous sildenafil in right ventricular dysfunction with pulmonary hypertension following a heart transplant.

Bonet LA, Guillén RV, Lázaro IS, de la Fuente C, Osseyran F, Dolz LM, Hernández MM, Sanz MP, Otero MR, Sanz AS.

Heart Int. 2014 Aug 11;9(1):22-5. eCollection 2014 Jan-Jun.

22.

Akt and ERK/Nrf2 activation by PUFA oxidation-derived aldehydes upregulates FABP4 expression in human macrophages.

Lázaro I, Ferré R, Masana L, Cabré A.

Atherosclerosis. 2013 Oct;230(2):216-22. doi: 10.1016/j.atherosclerosis.2013.07.043. Epub 2013 Aug 1.

PMID:
24075747
23.

Proposal for a frontal impact and compatibility assessment approach based on the European FIMCAR Project.

Johannsen H, Adolph T, Edwards M, Lazaro I, Versmissen T, Thomson R.

Traffic Inj Prev. 2013;14 Suppl:S105-15. doi: 10.1080/15389588.2013.790538.

PMID:
23906350
24.

Gene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice.

Mallavia B, Oguiza A, Lopez-Franco O, Recio C, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, Egido J, Gomez-Guerrero C.

PLoS One. 2013 Jun 21;8(6):e66754. doi: 10.1371/journal.pone.0066754. Print 2013.

25.

Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients.

Cabré A, Valdovinos P, Lázaro I, Bonet G, Bardají A, Masana L.

Cardiovasc Diabetol. 2013 May 4;12:72. doi: 10.1186/1475-2840-12-72.

26.

Peptide inhibitor of NF-κB translocation ameliorates experimental atherosclerosis.

Mallavia B, Recio C, Oguiza A, Ortiz-Muñoz G, Lazaro I, Lopez-Parra V, Lopez-Franco O, Schindler S, Depping R, Egido J, Gomez-Guerrero C.

Am J Pathol. 2013 May;182(5):1910-21. doi: 10.1016/j.ajpath.2013.01.022. Epub 2013 Apr 16. Erratum in: Am J Pathol. 2013 Jul;183(1):326.

PMID:
23597852
27.

In vivo cell reprogramming towards pluripotency by virus-free overexpression of defined factors.

Yilmazer A, de Lázaro I, Bussy C, Kostarelos K.

PLoS One. 2013;8(1):e54754. doi: 10.1371/journal.pone.0054754. Epub 2013 Jan 23.

28.

FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study.

Cabré A, Babio N, Lázaro I, Bulló M, Garcia-Arellano A, Masana L, Salas-Salvadó J.

Atherosclerosis. 2012 May;222(1):229-34. doi: 10.1016/j.atherosclerosis.2012.02.003. Epub 2012 Feb 24.

PMID:
22420890
29.

Lifestyle changes lower FABP4 plasma concentration in patients with cardiovascular risk.

Lázaro I, Ferré R, Plana N, Aragonès G, Girona J, Merino J, Heras M, Cabré A, Masana L.

Rev Esp Cardiol (Engl Ed). 2012 Feb;65(2):152-7. doi: 10.1016/j.recesp.2011.09.016. Epub 2011 Dec 5. English, Spanish.

PMID:
22153726
30.

Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.

Lázaro I, Díaz M, Cabré A, Masana L, Ibáñez L.

Gynecol Endocrinol. 2011 Nov;27(11):935-9. doi: 10.3109/09513590.2011.569608. Epub 2011 May 24.

PMID:
21605000
31.

Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes.

Aragonès G, Ferré R, Lázaro I, Cabré A, Plana N, Merino J, Heras M, Girona J, Masana L.

Atherosclerosis. 2010 Nov;213(1):329-31. doi: 10.1016/j.atherosclerosis.2010.07.026. Epub 2010 Jul 27.

PMID:
20723896
32.

EC treatment for reuse of tissue paper wastewater: aspects that affect energy consumption.

Terrazas E, Vázquez A, Briones R, Lázaro I, Rodríguez I.

J Hazard Mater. 2010 Sep 15;181(1-3):809-16. doi: 10.1016/j.jhazmat.2010.05.086. Epub 2010 May 25.

PMID:
20619795
33.

FABP4 plasma levels are increased in familial combined hyperlipidemia.

Cabré A, Lázaro I, Cofán M, Jarauta E, Plana N, Garcia-Otín AL, Ascaso JF, Ferré R, Civeira F, Ros E, Masana L.

J Lipid Res. 2010 May;51(5):1173-8. doi: 10.1194/jlr.M900066.

34.

APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome.

Castro A, Lázaro I, Selva DM, Céspedes E, Girona J, NúriaPlana, Guardiola M, Cabré A, Simó R, Masana L.

Atherosclerosis. 2010 Mar;209(1):201-5. doi: 10.1016/j.atherosclerosis.2009.09.072. Epub 2009 Oct 6.

PMID:
19878946
35.

The APOA5-1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes.

Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Guardiola M, Heras M, Masana L.

Nutr Metab Cardiovasc Dis. 2010 May;20(4):243-8. doi: 10.1016/j.numecd.2009.04.003. Epub 2009 Sep 17.

PMID:
19765959
36.

Antiphospholipid antibodies may impair factor XIIa-dependent activation of fibrinolysis in pregnancy: in vitro evidence with human endothelial cells in culture and monoclonal anticardiolipin antibodies.

Lázaro I, Carmona F, Reverter JC, Cervera R, Tassies D, Balasch J.

Am J Obstet Gynecol. 2009 Jul;201(1):87.e1-6. doi: 10.1016/j.ajog.2009.03.014. Epub 2009 May 8.

PMID:
19427615
37.

p53 regulates the self-renewal and differentiation of neural precursors.

Armesilla-Diaz A, Bragado P, Del Valle I, Cuevas E, Lazaro I, Martin C, Cigudosa JC, Silva A.

Neuroscience. 2009 Feb 18;158(4):1378-89. doi: 10.1016/j.neuroscience.2008.10.052. Epub 2008 Nov 7.

PMID:
19038313
38.

Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes.

Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L.

J Lipid Res. 2008 Aug;49(8):1746-51. doi: 10.1194/jlr.M800102-JLR200. Epub 2008 Apr 17.

39.

Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria.

Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L.

Clin Chem. 2008 Jan;54(1):181-7. Epub 2007 Nov 16.

40.

The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients.

Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragonés G, Parra S, Girona J, Masana L.

Atherosclerosis. 2008 Jul;199(1):147-53. Epub 2007 Nov 5.

PMID:
17983623
41.

Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes.

Cabré A, Lázaro I, Girona J, Manzanares J, Marimón F, Plana N, Heras M, Masana L.

J Intern Med. 2007 Oct;262(4):496-503.

42.

Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients.

Vila V, Martínez-Sales V, Almenar L, Lázaro IS, Villa P, Reganon E.

Int J Cardiol. 2008 Nov 12;130(2):276-7. Epub 2007 Aug 28. Erratum in: Int J Cardiol. 2011 Feb 3;146(3):484.

PMID:
17727986
43.

Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.

Vila V, Sales VM, Almenar L, Lázaro IS, Villa P, Reganon E.

Thromb Res. 2008;121(5):611-5. Epub 2007 Aug 10.

PMID:
17692904
44.

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.

Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L.

Atherosclerosis. 2007 Nov;195(1):e150-8. Epub 2007 Jun 5.

PMID:
17553506
45.

Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications.

Carmona F, Lázaro I, Reverter JC, Tàssies D, Font J, Cervera R, Balasch J.

Am J Obstet Gynecol. 2006 Feb;194(2):457-65.

PMID:
16458646
46.

Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases.

Carmona F, Font J, Moga I, Làzaro I, Cervera R, Pac V, Balasch J.

Am J Reprod Immunol. 2005 Apr;53(4):182-8.

PMID:
15760379
47.

[Perspectives in the treatment of allergy to latex: immunotherapy].

Tabar AI, Gómez B, Arroabarren E, Rodríguez M, Lázaro I, Anda M.

An Sist Sanit Navar. 2003;26 Suppl 2:97-102. Review. Spanish.

48.

Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis.

Bernal JA, Luna R, Espina A, Lázaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA.

Nat Genet. 2002 Oct;32(2):306-11. Epub 2002 Sep 23.

PMID:
12355087
49.

Involvement of p53 and interleukin 3 in the up-regulation of CD95 (APO-1/Fas) by X-ray irradiation.

Gutiérrez del Arroyo A, Gil-Lamagniere C, Lazaro I, de Marco MC, Layunta I, Silva A.

Oncogene. 2000 Jul 27;19(32):3647-55.

50.

Inhibition of human spleen protein tyrosine kinases by phenolic compounds.

Lázaro I, Palacios C, González M, González-Porqué P.

Anal Biochem. 1995 Feb 10;225(1):180-3. No abstract available.

PMID:
7778778

Supplemental Content

Loading ...
Support Center